Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
April 25, 2024 07:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as...
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer
November 13, 2023 03:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer Key appointment bringing 30 years of drug discovery and development expertise as the Company continues to build a...
Nucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the Board
September 06, 2023 03:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the Board Dr Greig brings more than 40 years of experience in the biopharmaceutical sectorExperienced Chair who has led...
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
October 19, 2022 02:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines Financing led by M Ventures...
Nucleome Therapeutics appoints Dr Phil Boyd as Chief Financial Officer
April 21, 2022 04:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr Phil Boyd as Chief Financial Officer Phil brings more than 20 years of top-flight financial experience in the life sciences industry Oxford, UK, 21 April 2022 –...
Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer
February 15, 2022 04:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer Nigel brings 20+ years of commercial and senior managerial experience in the biotech and pharma industry Oxford, UK, 15 February...
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
November 05, 2021 05:05 ET
|
Nucleome Therapeutics
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics Study conducted by Nucleome’s academic founders at the...
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
June 10, 2021 02:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature New method is being used by Nucleome to unlock the...
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
May 25, 2021 02:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board Nucleome’s unique technology platform has the potential to discover precision therapeutics...